^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    BCMA-targeted CAR-T immunotherapy

    Related drugs:
    1d
    AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1) (clinicaltrials.gov)
    P1/2, N=182, Recruiting, AstraZeneca | N=80 --> 182
    Enrollment change
    |
    AZD0120
    4d
    FUMANBA-04: Eque-cel for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=17, Not yet recruiting, Nanjing IASO Biotechnology Co., Ltd.
    New P1/2 trial
    |
    Fucaso (equecabtagene autoleucel)
    5d
    A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant (clinicaltrials.gov)
    P2, N=24, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    SDC1 (Syndecan 1)
    |
    Abecma (idecabtagene vicleucel)
    8d
    A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=30, Recruiting, Suzhou Immunofoco Biotechnology Co., Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    11d
    Idecabtagene vicleucel manufacturing and clinical value of out of specification products in relapsed and refractory MM. (PubMed, Blood Adv)
    ORR was 75.4% (95% CI, 63.1-85.2) and CRR was 35.4% (95% CI, 23.9-48.2). The manufacturing success of ide-cel is reliable and consistently high, and when OOS ide-cel products emerged, they demonstrated consistent clinical efficacy and safety.
    Journal
    |
    TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    Abecma (idecabtagene vicleucel)
    11d
    SLE-001: Descartes-08 for Patients With Systemic Lupus Erythematosus (clinicaltrials.gov)
    P2, N=6, Active, not recruiting, Cartesian Therapeutics | Trial completion date: Nov 2026 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Descartes-08
    13d
    LTFU: Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells (clinicaltrials.gov)
    P2/3, N=312, Recruiting, Celgene | N=214 --> 312
    Enrollment change
    |
    Breyanzi (lisocabtagene maraleucel) • Abecma (idecabtagene vicleucel)
    13d
    A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=30, Not yet recruiting, Suzhou Immunofoco Biotechnology Co., Ltd
    New P1/2 trial
    14d
    Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders (clinicaltrials.gov)
    P1/2, N=50, Recruiting, Cartesian Therapeutics | Trial completion date: Dec 2026 --> Dec 2028 | Trial primary completion date: Dec 2026 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    Descartes-08
    17d
    Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel) (clinicaltrials.gov)
    P1, N=40, Not yet recruiting, Washington University School of Medicine | Trial completion date: Jul 2028 --> Nov 2028 | Initiation date: Jan 2026 --> May 2026 | Trial primary completion date: Oct 2027 --> Feb 2028
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    clonoSEQ
    |
    Carvykti (ciltacabtagene autoleucel) • Hyleukin-7 (efineptakin alfa)
    25d
    A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel (clinicaltrials.gov)
    P2, N=60, Recruiting, Janssen Research & Development, LLC | Trial primary completion date: Jan 2028 --> Apr 2028
    Trial primary completion date
    |
    bortezomib • cyclophosphamide • Darzalex (daratumumab) • fludarabine IV • Carvykti (ciltacabtagene autoleucel)
    25d
    EPIC: Elranatamab in R/R Multiple Myeloma (clinicaltrials.gov)
    P2, N=32, Recruiting, Massachusetts General Hospital | Trial primary completion date: Dec 2025 --> Aug 2026
    Trial primary completion date
    |
    Elrexfio (elranatamab-bcmm) • Abecma (idecabtagene vicleucel)